Informational bulletin «Cardioprogress»

Informational bulletin «Cardioprogress»

Bulletin is published four times a year in both Russian and English (special issues) languages. 

It highlights the international and Russian scientific-practical conferences and events, opinion of experts on the issues of cardiology and public health, interviews with leading experts and news. In the pages of the bulletin the latest advances in medical technology, equipment and drug development are presented. 

The addressed spreading is free (Ministry of Health of the republics and regions of Russia, city health committees, medical universities, research institutes and specialized medical institutions, hospitals in Russia and CIS).

Contacts

Cardioprogress Foundation and Editorial Office:
Room 213, Building 2, Prospect Gostinichny 6, Moscow 127106, Russia Editorial Office
tel.: (+7) 965 236 1600 Official website: www.cardioprogress.ru
Editorial correspondence should be sent to:
Mehman Mamedov, Deputy Editor
editor.ihvdj@gmail.com

Issues

Scientific news

  • Weight Loss During Heart Failure Hospitalization Linked to Lower 30-Day Rehospitalization Risk Patients hospitalized for heart failure who were treated with intravenous loop diuretics and achieved a weight loss of at least 2 kg between admission and discharge had a reduced risk for HF rehospitalization within 30 days.
  • Allergic vasospastic angina: a systematic review Allergic vasospastic angina (also known as Kunis syndrome) is a little‑studied subtype of vasospastic angina in which spasm of the coronary arteries is triggered by an allergen. Scientists conducted a study in which they assessed the clinical characteristics, mechanisms, and treatment methods for this interesting subtype of angina.
  • Fitness Changes Over Time Linked to Cardiovascular Risk A large UK Biobank analysis showed that even a small annual improvement in cardiorespiratory fitness among adults was independently associated with lower risks for incident cardiovascular disease and cardiovascular mortality, whereas declining fitness was linked to a progressively higher risk in a clear dose-dependent pattern.
  • Cardioprotection Rarely Used in Adults With Blood Cancers In a US cohort study of adults on anthracycline-based therapy for hematologic cancers, only 1%-2% received strategies to lower the risk for treatment-related heart damage.
  • New horizons of cardiotherapy Since the introduction of the first implantable stimulator and defibrillator (ICD), cardiological science has advanced far. ICDs are highly effective, but their main disadvantage is the complications associated with the electrodes. To avoid the need for venous access and complications caused by transvenous electrodes, a fully subcutaneous ICD system (pc-ICD) was developed.

Partners

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru